Find and Pitch Jounalists, Get Your Story Covered

Tags: Novartis MHRA authorisation ribociclib Calypso Biotech acquisition

	Profile	Recent Articles on Subject
1	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots - 21 days ago Novartis Tries Again in Huntington’s, Putting Up $1B to Partner on a PTC Therapeutics Drug - 3 months ago Merck Is Paying $588M for Potential Successor to Cancer Drug Juggernaut Keytruda - 4 months ago Novartis to Pay $150M for Monte Rosa Glue Drug in the Clinic for Immunology Indications - 4 months ago Sanofi Jumps Into Radiopharmaceuticals, Paying €100M for Therapy That Could Rival a Novartis Drug - 6 months ago Novartis Extends Its Reach in Radiopharmaceuticals With $1B Mariana Oncology Acquisition - 10 months ago Novartis Pays $150M to Nab a Phase 3-Ready Protein Degrader for Prostate Cancer - 11 months ago
2	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Novartis secures MHRA authorisation for ribociclib - 27 days ago Novartis gene therapy set to enhance SMA treatment - about 2 months ago
3	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound - about 2 months ago AstraZeneca falls on reports of Chinese probe - 4 months ago STAT+: A ‘vaccine-like’ version of Wegovy is on the drawing board at Novo Nordisk - about 1 year ago STAT+: What comes after Wegovy? The quest to eradicate obesity - about 1 year ago STAT+: Novo Nordisk wants to be a cardiovascular company, too, with sights set on inflammation - over 1 year ago STAT+: Our expensive obesity drugs are worth it, Novo Nordisk and Eli Lilly argue in raft of studies - over 1 year ago
4	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about Novo and GLP-1 compounding, Paxlovid and long Covid, and more - about 2 months ago STAT+: Novo Holdings is set to close its $16.5 billion acquisition of Catalent after FTC declines to challenge the deal - 3 months ago STAT+: European regulators approve $16.5 billion deal for Novo Holdings to buy Catalent - 3 months ago STAT+: Pharmalittle: We’re reading about menopause treatments, Novo plans for Wegovy in India, and more - 3 months ago STAT+: Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more - 3 months ago STAT+: Catalent tries to reassure customers about its deal with Novo Holdings - 4 months ago STAT+: Pharmalittle: We’re reading about a Vaxcyte vaccine, Ozempic shortages, and more - 6 months ago STAT+: Pharmalittle: We’re reading about a Pfizer daily weight loss pill, a Novo Nordisk setback, and more - 8 months ago STAT+: U.K. trade group scolds Novo, Novartis, Pfizer, and Otsuka for violating industry codes - 8 months ago STAT+: Pharmalittle: We’re reading about Ozempic and an eye condition, a failed Roche cancer drug trial, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Sanders dogging Novo Nordisk, Teva patents, and more - 9 months ago STAT+: Pharmalittle: We’re reading about a Novo Nordisk deal, a Regeneron setback, and more - 11 months ago STAT+: Pharmalittle: We’re reading about a failed schizophrenia drug trial, a Pfizer cancer drug, and more - 12 months ago STAT+: Pharmalittle: We’re reading about Wegovy approved for heart risks, an ALS drug puzzle, and more - 12 months ago STAT+: Pharmalittle: We’re reading about India-made versions of Wegovy, an RSV vaccine scramble, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about GLP-1 drugs’ safety, Novartis nixing a deal, and more - about 1 year ago STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - about 1 year ago STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO - about 1 year ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - about 1 year ago STAT+: Pharmalittle: Roche to buy obesity-drug developer for $2.7 billion; Novo Nordisk paid U.S. doctors $26 million over a decade - about 1 year ago STAT+: Pharmalittle: AbbVie buys Immunogen, maker of targeted cancer drugs; Novo sues two more compounders - over 1 year ago STAT+: Pharmalittle: Wegovy cuts heart attack risk in milestone trial; AstraZeneca prioritizes U.S. for RSV drug amid surge - over 1 year ago STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya - over 1 year ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - over 1 year ago STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation - over 1 year ago STAT+: Pharmalittle: Novo Nordisk sees “significantly” more Wegovy in the U.S. next year; U.S. pharma layoffs skyrocket - over 1 year ago STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell - over 1 year ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - over 1 year ago STAT+: Novartis claims Takeda is stonewalling efforts to review trade secrets taken by a former employee - over 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - over 1 year ago STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’ - over 1 year ago STAT+: Judge dismisses Novo Nordisk lawsuit over compounded versions of Ozempic and Wegovy - over 1 year ago STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages - over 1 year ago STAT+: Pharmalittle: FDA finds problems at Novo’s main U.S. factory; polarizing ALS drug heads for FDA scrutiny - over 1 year ago STAT+: Novartis is scolded by U.K. trade group for the fourth time this year over Entresto promotions - over 1 year ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - over 1 year ago STAT+: Pharmalittle: U.S. Chamber and feds clash on Medicare price negotiation; South Africa probes J&J over TB-drug pricing - over 1 year ago
5	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Merck is a new year outlier with its diabetes drug - about 2 months ago STAT+: Potential competition for RSV prophylactic Beyfortus - 5 months ago Novartis reportedly decides to pass on Cytokinetics - about 1 year ago Novartis is building a new radioligand plant in China - about 1 year ago
6	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Novartis to pay $1 billion upfront to license Huntington’s drug from PTC - 3 months ago STAT+: Novartis, Seagen veteran David Epstein is back, leading a new cancer startup - 4 months ago STAT+: Novo Nordisk to acquire heart disease-focused Cardior Pharmaceuticals in deal worth $1.1 billion - 11 months ago STAT+: What comes after Wegovy? The quest to eradicate obesity - about 1 year ago STAT+: Results on Novartis prostate cancer therapy could expand its use - over 1 year ago
7	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Novartis buys gene therapy startup Kate Therapeutics, joining pursuit of muscular dystrophy treatment - 3 months ago STAT+: Novartis to buy German biotech MorphoSys for $2.9 billion - about 1 year ago STAT+: Could sickle cell someday be treated not with CRISPR, but with a pill? - about 1 year ago
8	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Backlash builds against Novo’s Catalent takeover - 4 months ago
9	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance - 6 months ago STAT+: Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs - about 1 year ago
10	Adam Spatacco Motley Fool Community for top investors. Investingcommunity	Did Eli Lilly Just Get a Leg Up on Novo Nordisk? - 8 months ago Novo Nordisk Just Scored a Huge Win. And It's Not Related to Ozempic - 12 months ago Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited - about 1 year ago

Journalists covering Novartis